"Gamble et al. have published the first study that helps us to evaluate the survival benefit and cost-effectiveness of RRM among women with BRCA1 and BRCA2 mutations following stage II–IV ovarian cancer."
"Among women older than age 60 years who are diagnosed with ovarian cancer, the incremental cost-effectiveness ratio (ICER) exceeds a generally accepted willingness to pay threshold of $100,000–$200,000 per year of life saved (YLS) in most scenarios and the benefit of RRM was negligible. The added benefit of RRM in terms of survival gain in months was greatest in women aged 40 years..."
The current (Mayo Clinic Rochester) recommendations for managing these patients are summarized above.